Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non-Current Deffered Revenue (2018 - 2025)

Arcturus Therapeutics Holdings' Non-Current Deffered Revenue history spans 8 years, with the latest figure at $4.2 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 68.36% year-over-year to $4.2 million; the TTM value through Sep 2025 reached $4.2 million, down 68.36%, while the annual FY2024 figure was $12.6 million, 70.34% down from the prior year.
  • Non-Current Deffered Revenue reached $4.2 million in Q3 2025 per ARCT's latest filing, down from $8.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $42.5 million in Q4 2023 to a low of $4.2 million in Q3 2025.
  • Average Non-Current Deffered Revenue over 5 years is $15.2 million, with a median of $11.3 million recorded in 2024.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 709.25% in 2023, then tumbled 70.34% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $19.9 million in 2021, then rose by 0.7% to $20.1 million in 2022, then skyrocketed by 111.73% to $42.5 million in 2023, then crashed by 70.34% to $12.6 million in 2024, then plummeted by 66.52% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Non-Current Deffered Revenue are $4.2 million (Q3 2025), $8.8 million (Q2 2025), and $9.6 million (Q1 2025).